Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Haematological Malignancies Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
 
John C. Byrd, Peter Hillmen, Paolo Ghia,  et al.
Clinical trial information: NCT02477696
 
Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.
 
Paolo Ghia, John N. Allan, Tanya Siddiqi,  et al.
 Clinical trial information: NCT02910583
 
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
 
Sikander Ailawadhi, Asher Alban Akmal Chanan-Khan, Zi Chen, et al.
 Clinical trial information: NCT03537482
 
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.
 
Mitchell Reed Smith, Opeyemi Jegede, Peter Martin,  et al.
Clinical trial information: NCT01415752
 
Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice.
 
Peter Martin, Michael Wang, Anita Kumar,  et al.
 
 
The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.
 
Tycel Jovelle Phillips, Alexey Valeryevich Danilov, David Alan Bond, et al.
 Clinical trial information: NCT03523975
 
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).
 
Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, et al.
Clinical trial information: NCT01511562
 
CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
 
Ann S. LaCasce, Travis Dockter, Amy S. Ruppert, et al.
. Clinical trial information: NCT01118026
 
Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
 
Stephen J. Schuster, Michael J. Dickinson, Martin H. Dreyling, et al.
 Clinical trial information: NCT03568461